NCT03832114View on ClinicalTrials.gov

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

April 23, 2021

Study Completion Date

April 23, 2021

Conditions
Glomerulonephritis
Interventions
DRUG

LNP023

Increasing doses of LNP023 up to 200 mg.

Trial Locations (9)

24020

Novartis Investigative Site, Ranica

28041

Novartis Investigative Site, Madrid

34295

Novartis Investigative Site, Montpellier

45147

Novartis Investigative Site, Essen

52242

Novartis Investigative Site, Iowa City

75015

Novartis Investigative Site, Paris

08035

Novartis Investigative Site, Barcelona

W12 0NN

Novartis Investigative Site, London

NE7 7DN

Novartis Investigative Site, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY